Novartis ADR saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, with an increase from 69 to 76.
Can You Really Time The Stock Market?
This exclusive rating from Investor's Business Daily tracks price movement with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves. See if Novartis ADR can continue to show renewed price strength and hit that benchmark.
Novartis ADR has moved more than 5% past a 116.91 entry in a first-stage consolidation, meaning it's now out of a proper buy zone. Look for the stock to offer a new chance to get in like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company posted 27% earnings growth last quarter, while sales growth came in at 12%. The next quarterly numbers are expected on or around Jul. 17.
The company earns the No. 2 rank among its peers in the Medical-Ethical Drugs industry group. Phibro Animal Health is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
